Arbutus Biopharma
arbutusbio.com
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Arbutus Biopharma Science & TechnologyNOCA
ALPHA Overview of TechnologyWhat is Arbutus Biopharma's SciTech?From "suppressing" chronic hepatitis B to "achieving treatment cessation"The science and technology that Arbutus Biopharma currently centers its development on is treatment using RNA interfer
Read more
Report
Arbutus Biopharma Announces Major Share Repurchase Tender Offer
Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.
Read more
Report
Arbutus Biopharma Reports Positive Phase 2a Results for Imdusiran in Combination with VTP-300 and Low Dose Nivolumab in Chronic Hepatitis B Patients at EASL 2025
Imdusiran combined with VTP-300 and nivolumab shows promise for achieving functional cures in chronic hepatitis B patients.
Read more
Report
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Read more
Report
Cramer's Lightning Round: Arbutus Biopharma is 'the ultimate spec'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
Read more
Report